Why Is AMYLYX PHARMACEUTICA (AMLX) Stock Up Today?

AMLX stock surged 53.17% to $32.83 in a volatile session driven by positive Phase 3 trial results for its experimental GLP-1 blocker Avexitide and multiple analyst upgrades. The stock opened with a 44.7% gap up and reached an intraday high of $32.98 before settling near $32.79. Analysts from H.C. Wainwright and Stifel raised price targets, while Citi and Stifel expressed optimism about potential FDA approval based on the data.

What Happened

Amylyx Pharmaceuticals announced positive results from its pivotal Phase 3 trial for Avexitide, an experimental therapy for post-bariatric hypoglycemia. The trial met its primary endpoint, sparking investor enthusiasm and a sharp rise in the stock. The company also set a date for the topline results announcement of its LUCIDITY trial on August 18, 2026, which has generated further speculation about the drug's potential. Analysts at H.C. Wainwright raised the price target to $55 from $34, and Stifel increased its target to $45 from $21. Citi and Stifel both described the data as supporting a best-case scenario and potential regulatory approval.

What The Data Shows

The stock opened at $31.00, a 44.7% jump from the prior close of $21.43. It reached an intraday high of $32.98 before retreating slightly. The session volume was 13.5 million shares, which is 8.9 times the 3-month daily average. Over the last 8 sessions, the stock had declined 1.0% from $21.85 to $21.63. The 52-week tape showed 26 fresh 52-week highs and 6 fresh 52-week lows on August 18. Recent insider activity includes one sale totaling $539K by Gina Mazzariello on July 9.

What To Watch

The company is scheduled to release topline results from its LUCIDITY trial on August 18, 2026. Investors will closely monitor this event for further validation of Avexitide’s potential. Coverage breadth remains high, with 26 stories from 10 sources in the last 36 hours.